These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31545969)

  • 1. Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide.
    Yang S; Chen Y; Feng M; Rodriguez L; Wu JQ; Wang MZ
    J Pharm Sci; 2019 Dec; 108(12):3870-3878. PubMed ID: 31545969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides.
    Kiptoo P; Sinaga E; Calcagno AM; Zhao H; Kobayashi N; Tambunan US; Siahaan TJ
    Mol Pharm; 2011 Feb; 8(1):239-49. PubMed ID: 21128658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability.
    Laksitorini MD; Kiptoo PK; On NH; Thliveris JA; Miller DW; Siahaan TJ
    J Pharm Sci; 2015 Mar; 104(3):1065-75. PubMed ID: 25640479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain.
    Alaofi A; On N; Kiptoo P; Williams TD; Miller DW; Siahaan TJ
    J Pharm Sci; 2016 Feb; 105(2):797-807. PubMed ID: 26869430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the selectivity of HAV-peptides in modulating E-cadherin-E-cadherin interactions in the intercellular junction of MDCK cell monolayers.
    Makagiansar IT; Avery M; Hu Y; Audus KL; Siahaan TJ
    Pharm Res; 2001 Apr; 18(4):446-53. PubMed ID: 11451030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible Opening of Intercellular Junctions of Intestinal Epithelial and Brain Endothelial Cells With Tight Junction Modulator Peptides.
    Bocsik A; Walter FR; Gyebrovszki A; Fülöp L; Blasig I; Dabrowski S; Ötvös F; Tóth A; Rákhely G; Veszelka S; Vastag M; Szabó-Révész P; Deli MA
    J Pharm Sci; 2016 Feb; 105(2):754-765. PubMed ID: 26869428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Delivery of Drug and MRI Contrast Agent: Detection and Quantitative Determination of Brain Deposition of CPT-Glu Using LC-MS/MS and Gd-DTPA Using Magnetic Resonance Imaging.
    Tabanor K; Lee P; Kiptoo P; Choi IY; Sherry EB; Eagle CS; Williams TD; Siahaan TJ
    Mol Pharm; 2016 Feb; 13(2):379-90. PubMed ID: 26705088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
    Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
    Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors.
    Sajesh BV; On NH; Omar R; Alrushaid S; Kopec BM; Wang WG; Sun HD; Lillico R; Lakowski TM; Siahaan TJ; Davies NM; Puno PT; Vanan MI; Miller DW
    Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31533285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat.
    Johansson CC; Gennemark P; Artursson P; Äbelö A; Ashton M; Jansson-Löfmark R
    J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):117-28. PubMed ID: 23307171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.
    Watkins ME; Wring S; Randolph R; Park S; Powell K; Lutz L; Nowakowski M; Ramabhadran R; Domanico PL
    J Pharm Sci; 2017 Mar; 106(3):906-919. PubMed ID: 27986599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
    Kamath AV; Chong S; Chang M; Marathe PH
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microcontainers for oral insulin delivery - In vitro studies of permeation enhancement.
    Jørgensen JR; Jepsen ML; Nielsen LH; Dufva M; Nielsen HM; Rades T; Boisen A; Müllertz A
    Eur J Pharm Biopharm; 2019 Oct; 143():98-105. PubMed ID: 31425857
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ulapane KR; Kopec BM; Siahaan TJ
    Mol Pharm; 2019 Dec; 16(12):4878-4889. PubMed ID: 31664837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley rats.
    Al-Ali AAA; Quach JRC; Bundgaard C; Steffansen B; Holm R; Nielsen CU
    Int J Pharm; 2018 May; 543(1-2):352-360. PubMed ID: 29635055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats.
    Hyung S; Jeong YS; Yeo J; Song YK; Kim MS; Im YJ; Maeng HJ; Chung SJ
    Eur J Pharm Sci; 2018 Oct; 123():312-320. PubMed ID: 30056192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing paracellular porosity by E-cadherin peptides: discovery of bulge and groove regions in the EC1-domain of E-cadherin.
    Sinaga E; Jois SD; Avery M; Makagiansar IT; Tambunan US; Audus KL; Siahaan TJ
    Pharm Res; 2002 Aug; 19(8):1170-9. PubMed ID: 12240943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive self-assembling lipid-like peptides as permeation enhancers for oral drug delivery.
    Karavasili C; Spanakis M; Papagiannopoulou D; Vizirianakis IS; Fatouros DG; Koutsopoulos S
    J Pharm Sci; 2015 Jul; 104(7):2304-11. PubMed ID: 25994901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models.
    Hellinger E; Veszelka S; Tóth AE; Walter F; Kittel A; Bakk ML; Tihanyi K; Háda V; Nakagawa S; Duy TD; Niwa M; Deli MA; Vastag M
    Eur J Pharm Biopharm; 2012 Oct; 82(2):340-51. PubMed ID: 22906709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.